Working… Menu
Help guide our efforts to modernize
Send us your comments by March 14, 2020.
Trial record 6 of 7 for:    "Lung Disease" | "Metoprolol"

Beta-Blocker in Chronic Obstructive Pulmonary Disease (COPD) Study (BOLD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00745043
Recruitment Status : Completed
First Posted : September 1, 2008
Last Update Posted : September 1, 2008
Waikato Hospital Research Fund
Information provided by:
Waikato Hospital

Brief Summary:
Smoking causes both smoking related lung disease (COPD) and ischaemic heart disease. These are very common conditions and many patients have both diseases. Beta-blocker drugs are extensively used in the treatment of angina, high blood pressure and after heart attacks to decrease symptoms and prolong life. Beta-agonists are used in COPD to decrease breathlessness and improve exercise tolerance. It used to be thought that beta-blockers cannot be used in COPD patients as they may make the breathlessness worse, but it has now been established that they can be used safely. Beta-blocker drugs and beta-agonists have 'opposite' effects on the body and the investigators do not know if they can work together or if they would cancel each other out. The investigators also do not know which of the different types of beta-blockers now available are better for COPD patients. This study will investigate what happens to the airways of people taking both of these drugs.

Condition or disease Intervention/treatment Phase
Chronic Obstructive Pulmonary Disease Drug: bronchodilator response Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 11 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Do Beta-Blockers Affect the Use of Beta-Agonist Inhalers in COPD?
Study Start Date : May 2005
Actual Primary Completion Date : August 2007
Actual Study Completion Date : August 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Lung Diseases

Arm Intervention/treatment
Placebo Comparator: R302
Daily placebo capsules
Drug: bronchodilator response
Active Comparator: R303
Daily metoprolol 95mg capsules
Drug: bronchodilator response
Active Comparator: R304
Daily propranolol 80mg capsules
Drug: bronchodilator response
Active Comparator: Open Label
Daily Metoprolol 190mg capsules
Drug: bronchodilator response

Primary Outcome Measures :
  1. Bronchodilator response to salbutamol after beta-blockers [ Time Frame: 7-10 days ]
  2. Incremental Shuttle Walk Test Result after taking beta-blockers [ Time Frame: 7-10 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Clinical diagnosis of COPD
  • > 40 years of age
  • > 15 pack year smoking history

Exclusion Criteria:

  • Contra-indication to beta-blocker use
  • Severe COPD FEV1 < 30% or 1 L
  • Not responsive the methacholine

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00745043

Layout table for location information
New Zealand
Department of Respiratory Medicine
Hamilton, Waikato, New Zealand, 3204
Sponsors and Collaborators
Waikato Hospital
Waikato Hospital Research Fund
Layout table for investigator information
Study Director: Bob Hancox, MD FRACP Waikato Hospital Research Unit

Layout table for additonal information
Responsible Party: Dr Catherina Chang Research Fellow, Respiratory Research Waikato Hospital Identifier: NCT00745043    
Other Study ID Numbers: NTX/05/04/035
First Posted: September 1, 2008    Key Record Dates
Last Update Posted: September 1, 2008
Last Verified: August 2008
Keywords provided by Waikato Hospital:
exercise capacity
methacholine challenge
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Bronchodilator Agents
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents